Euroapi SAS
PAR:EAPI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Euroapi SAS
PAR:EAPI
|
FR |
|
Kenadyr Mining Corp
XTSX:KEN
|
CA |
|
Nutranomics Inc
OTC:NNRX
|
US |
|
M
|
MQ Technology Bhd
KLSE:MQTECH
|
MY |
|
A
|
Aluminum Corporation of China Ltd
SWB:AOC
|
CN |
|
K
|
Kajima Corp
F:KAJ
|
JP |
Euroapi SAS
Euroapi SAS makes active pharmaceutical ingredients, or APIs, which are the main chemical substances used in medicines. It also helps drug makers develop and manufacture certain complex molecules. In simple terms, Euroapi sits in the middle of the pharmaceutical supply chain: it turns chemistry into the building blocks that other companies use to make finished drugs. Its customers are mainly pharmaceutical companies, generic drug makers, and some healthcare groups that need a reliable source of regulated ingredients. Euroapi sells these ingredients and related manufacturing services under long-term supply relationships and project work tied to specific molecules. The company’s money comes from producing APIs, customizing them for customer needs, and supporting development and manufacturing programs. What makes Euroapi distinct is its focus on large-scale pharmaceutical chemistry rather than branded medicines. It works in a highly regulated industry where quality, traceability, and consistent supply matter as much as the chemical product itself. That makes Euroapi less like a consumer drug company and more like a specialized industrial supplier to the medicines market.
Euroapi SAS makes active pharmaceutical ingredients, or APIs, which are the main chemical substances used in medicines. It also helps drug makers develop and manufacture certain complex molecules. In simple terms, Euroapi sits in the middle of the pharmaceutical supply chain: it turns chemistry into the building blocks that other companies use to make finished drugs.
Its customers are mainly pharmaceutical companies, generic drug makers, and some healthcare groups that need a reliable source of regulated ingredients. Euroapi sells these ingredients and related manufacturing services under long-term supply relationships and project work tied to specific molecules. The company’s money comes from producing APIs, customizing them for customer needs, and supporting development and manufacturing programs.
What makes Euroapi distinct is its focus on large-scale pharmaceutical chemistry rather than branded medicines. It works in a highly regulated industry where quality, traceability, and consistent supply matter as much as the chemical product itself. That makes Euroapi less like a consumer drug company and more like a specialized industrial supplier to the medicines market.
Sales: Euroapi reported first-half net sales of EUR 356 million, down 13.5% year on year, as portfolio exits, softer demand in some products, and the Haverhill divestment weighed on revenue.
Profitability: Core EBITDA was EUR 20.7 million, with a 5.8% margin, while reported EBITDA was negative EUR 43.1 million because of transformation and restructuring costs tied to FOCUS-27.
Outlook: Management left full-year sales guidance unchanged at down around 10% on a comparable basis, but lowered the core EBITDA margin outlook to around 6% at constant perimeter because of the stronger-than-expected Hungarian forint.
Transformation: FOCUS-27 continued to move ahead with site optimization, cost cuts, and the signed agreement to divest Brindisi, which management said is a key milestone in simplifying the company.
Demand mix: Management said part of the weakness in API solutions is structural, especially for commoditized small molecules, while some demand softness is temporary and linked to customer destocking after the post-COVID period.
CDMO: CDMO sales grew 2% in the half and management said it is seeing encouraging momentum, more RFPs, and early interest in using idle fermentation capacity at Elbeuf.
Liquidity: Euroapi ended the half with net debt of EUR 37.9 million, but management said it still has plenty of headroom under its EUR 451 million RCF and expects full-year cash flow to be in line with original assumptions.
